Eli Lilly sees big potential in severe obesity candidates

The US-based pharmaceutical firm has two obesity candidates in its pipeline.
Photo: Mike Blake/Reuters/Ritzau Scanpix
Photo: Mike Blake/Reuters/Ritzau Scanpix

American pharmaceutical company Eli Lilly expects to steal Novo Nordisk’s lead in the obesity treatment market where, if all goes well, Lilly could launch two new weight loss drugs in 2026.

Patrik Jonsson, Executive Vice President of Eli Lilly within diabetes and obesity, has a lot of faith in Eli Lilly’s drug candidates retatrutide and orforgliprone. 

”I feel extremely good about the cards we have in our hand. Extremely good. I think we have winning cards in our hand, and two of them are retatrutide and orforgliprone,” Patrik Jonsson tells Danish business Finans. 

Zealand Pharma, Boehringer Ingelheim and Pfizer are also developing obesity drugs, while Novo Nordisk is testing its bestseller substance semaglutide in other indications. 

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading